| 证券代码 | ARDM.O |
| 证券名称 | Aradigm Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2014-06-11 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Aradigm Corporation |
| 注册地址 | 美国加利福尼亚州 |
| 办公地址 | 3929 Point Eden Way, Hayward, California, USA |
| 成立日期 | 1991 |
| 董事会主席 | John M. Siebert |
| 公司属地 | United States 美国 |
| 公司网址 | www.aradigm.com |
| 电话 | +1 (510) 265-9000 |
| 传真 | +1 (510) 265-8878 |
| 公司简介 | Aradigm Corporation is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm has completed two Phase 3 trials with Linhaliq, an investigational proprietary formulation of ciprofloxacin for inhalation for the treatment of non-cystic fibrosis BE and submitted an NDA to the FDA on July 27, 2017 for this indication. The FDA responded with a CLR regarding the NDA. As stated previously, they are committed to continuing to work on obtaining regulatory approval of Linhaliq in the US. |